Tocagen Fails Brain Cancer Test and Launches "Operational Review" When Routing Actions
[ad_1] It was still difficult to treat brain cancer and let a lot of failures go by, but Tocagen inevitably saw his attempt fail, leading to a re-examination of his operations. Tocagen recently transferred its gene therapy assets, Toca 511 and Toca FC, into a phase 3 trial targeting patients with recurrent high-grade glioma (HGG) … Read more